Hospitals sue again over 340B rebates. Plan as if the pilot starts Jan. 1
- Posted by Greg Wahlstrom, MBA, HCM
- Posted in Blog
Hospitals have asked a federal court to stop HHS’s expanded 340B rebate pilot, but with a Jan. 1 start date, finance and pharmacy teams cannot wait for a ruling.
A second lawsuit over the same idea
On Oct. 9, the American Hospital Association, the Maine Hospital Association and four safety-net hospitals filed suit in the U.S. District Court for the District of Maine to block the Health Resources and Services Administration’s revised 340B Rebate Model Pilot Program. It is the hospital field’s second challenge to the concept. A narrower 2025 version was halted after that court and the 1st Circuit faulted HHS for not adequately accounting for hospital costs, and HHS later withdrew it.
The new version is broader. On Oct. 1, HRSA published approved plans from 10 drugmakers, including Pfizer, AbbVie, Merck and AstraZeneca, covering high-use drugs drawn from the Medicare price negotiation list. Most are retail Part D products; Part B infused drugs are not included. The pilot is scheduled to begin Jan. 1, 2027.
Why it matters to the balance sheet
The model changes when hospitals receive their 340B savings, not just how. Covered entities would buy pilot drugs at wholesale acquisition cost through their 340B accounts, then receive the discount later as a rebate once a complete, claim-level submission is verified in the manufacturer’s system. Claims data generally must be submitted within 45 days of dispensing.
That moves cash from hospitals to manufacturers for the length of the rebate cycle and adds a new stream of data submissions, denials and reconciliation. Hospitals estimate the field-wide administrative burden at more than $1 billion a year. The pressure is coming from several directions at once: an HHS policy report released last week argued the program has grown beyond its original purpose, and CMS has proposed making submissions to its new Part D 340B claims data repository mandatory starting Jan. 1. Those moves land on top of the 340B payment changes CMS proposed in its 2027 outpatient rule.
What to do before Jan. 1
- Model the float. Estimate annual 340B savings on the pilot drugs and test cash flow under several rebate-lag and denial-rate assumptions.
- Lock down purchasing. Confirm pilot drugs are ordered only through 340B wholesaler accounts, not WAC-only or GPO accounts, including automated reorders at clinics and contract pharmacies.
- Build the data pipeline. Test claim-level submissions now and assign clear ownership for denials, appeals and reconciliation. Manufacturers must document their reasons for denied claims, so track them.
- Decide on the CMS repository. Choose whether to submit voluntarily ahead of the proposed mandate, and validate data quality first.
- Brief the board. Show how much of the 340B benefit now depends on manufacturer systems and on the outcome of the lawsuit.
Executive takeaway: Treat the lawsuit as possible upside, not a plan. Assume rebates start Jan. 1, quantify the cash-flow lag, and make sure purchasing and claims data are ready either way.
Sources
- AHA, others file suit to stop costly 340B rebate program from harming hospitals and patients (AHA News, Oct 9, 2026)
- Hospitals sue – again – to halt Trump administration’s 340B rebate pilot (STAT, Oct 9, 2026)
- HRSA names 10 drugmakers for revised 340B rebate pilot ahead of 2027 launch (Fierce Healthcare, Oct 2, 2026)
- 340B Rebate Pilot — The Clock Starts Now (Mintz, Oct 7, 2026)
- Fierce Healthcare Regulatory Recap: CMS releases 2027 MA star ratings (Fierce Healthcare, Oct 9, 2026)
